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Abstract 
 
Pulmonary arterial hypertension (PAH) occurs in approximately 10% of 
patients with systemic sclerosis (SSc). Annual screening with pulmonary 
function tests (PFT) is recommended to help identify those patients at risk of 
PAH. We have noted that patients with SSc who carry anti-centromere 
autoantibodies (ACA) often have PFT abnormalities, in the absence of clinical 
evidence of PAH. To evaluate this further, we undertook a retrospective case-
control study evaluating PFT results in patients with SSc in whom pulmonary 
complications have neither been diagnosed nor suspected. Patients were 
divided according to ACA carriage and groups compared for PFT results. The 
median forced vital capacity (FVC) was higher in ACA positive patients (106% 
vs. 93%, p=0.004). The gas transfer factor (TLco) was significantly lower in 
the ACA group (62.5% vs. 71%, p=0.013). The resulting FVC:TLco was 
significantly higher for ACA positive vs. ACA negative patients with SSc (1.70 
vs. 1.29, p<0.001). Our findings suggest patients carrying ACA, without 
established or suspected pulmonary complications, have PFT abnormalities 
consistent with indolent increased pulmonary vascular resistance despite the 
majority of such patients not subsequently developing PAH. The long-term 
sequalae of PFT abnormalities in those patients with ACA who do not 
subsequently develop PAH is unknown. 
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Introduction  
 
Pulmonary arterial hypertension (PAH) is a recognised complication of 
systemic sclerosis (SSc) with an estimated prevalence of between twelve and 
fifteen percent (1, 2). Pulmonary arterial hypertension (PAH) is defined as a 
mean pulmonary artery pressure of >25mmHg at rest with a pulmonary 
capillary wedge pressure of less than or equal to 15mmHg and a pulmonary 
vascular resistance greater than 3 Wood units (3). Assessment of pulmonary 
arterial pressure (PAP) requires invasive right heart catheterisation (RHC) 
which has led to the emergence of non-invasive techniques, such as trans-
thoracic echocardiography (TTE), as screening tools in the assessment of 
possible PAH. Annual assessment of PFT and TTE is recommended as 
screening for PAH in asymptomatic patients with SSc (4). We have noted that 
patients with SSc who carry anti-centromere autoantibodies (ACA) often have 
pulmonary function test abnormalities in the absence of clinical evidence of 
PAH. To confirm these observations, we have undertaken a retrospective 
case-control study evaluating PFT results of SSc patients, with or without 
ACA, in whom pulmonary complications have neither been diagnosed nor 
suspected.  
 
 
Materials and Methods 
 
A retrospective review of all patients with systemic sclerosis who had 
attended out-patient clinic over the previous year was undertaken. Case notes 
of patients who had provided written consent for inclusion on our CTD 
database were reviewed. The use of such retrospective clinical data has 
received approval from the Bath Research Ethics Committee. Notes were 
scrutinised for autoantibody specificity, age, most recent PFT and TTE 
results, and extent of cutaneous involvement according to the LeRoy and 
Medsger criteria.(5) We were unable to verify the presence of respiratory 
symptoms due to inconsistent documentation. Patients with established ILD 
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(confirmed on HRCT) or PAH (mean PAP at RHC of >25mmHg) were 
excluded from analysis. Similarly, patients awaiting investigation for these 
complications were excluded from subsequent analysis. The remaining 
patients were divided according to ACA carriage and a comparison of clinical 
features and PFT results from the 2 groups was undertaken.  
 
Statistical analysis 
 
All data is presented as median [IQR] unless otherwise stated. All PFT data is 
reported as % predicted. The Mann Whitney U test was used to compare the 
distribution of values across ACA positive and ACA negative patient 
populations. All tests were 2-tailed and a p value of <0.05 was considered 
statistically significant.  
 
 Results 
 
The case-notes of 93 patients with SSc were reviewed. Thirty patients were 
excluded; 17 with ILD, 9 with PAH, 2 with coexistent ILD and PAH, and 1 
patient who was awaiting RHC assessment for possible PAH. One patient 
with systemic sclerosis secondary to post-bone marrow transplantation graft 
versus host disease was also excluded. Of the remaining 63 patients, 34 
patients (53.9%) were ACA positive. The remainder carried a variety of anti-
nuclear antibody (ANA) specificities which included anti-Scl-70 (n=5), anti-U3-
RNP (n=4), anti-PM-Scl (n=3) anti-U1-RNP (n=2), anti-RNA Polymerase III 
(n=1), anti-Th/To (n=1), other SSc-related ANA (n=4), uncharacterised ANA 
(n=8) and one patient with negative ANA (n=1) The majority of patients in 
each group had limited cutaneous involvement (33/34 vs. 27/29, p=0.59). As 
expected, the median age was higher in the ACA group (63 vs. 57 years, 
p=0.031).   
 
Fifty-nine patients (59/63, 93.6%) had undergone previous PFTs (a median 
number of 231 [147-523] days prior to assessment). The median FVC was 
higher in patients carrying ACA (106% [21.5] vs. 93% [18.75], p=0.004). The 
TLco meanwhile was significantly lower in the ACA group (62.5% [14.75] vs. 
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71% [16.65], p=0.013). The resulting FVC:TLco was significantly higher in the 
ACA group (1.7 [0.45] vs. 1.29 [0.30], p<0.001, Figure 1.). Fifty-nine patients 
(59 /63, 93.6%) had undergone a previous echo (median of 364 [144-659] 
days prior to assessment). An estimated RVSP was reported in 22/59 (37.3%) 
of cases (n=17 for ACA positive and n=5 for ACA negative patients). The 
median estimated RVSP on TTE, when available from the TTE report, did not 
differ between groups (24 [11] mmHg vs. 30 [12]mmHg, p=0.45).  
 
Discussion 
 
PFT findings have been shown to be major predictors of PAH in SSc, 
particularly when the FVC:TLco ratio exceeds 2.0 (2, 7). To our knowledge, 
this is the first case-control study to evaluate the influence of ACA-carriage on 
PFT results in patients with SSc, in whom pulmonary disease has neither 
been diagnosed nor suspected. In our cohort ACA carriage was associated 
with a higher FVC, lower TLco and an elevated FVC:TLco. The higher FVC 
may be explained by a lower prevalence of sub-clinical lung fibrosis in 
patients with ACA. Alternative explanations for the apparent supranormal FVC 
in ACA positive patients could be sought from further studies incorporating 
imaging assessment of these patient groups. The reduced TLco and elevated 
FVC:TLco are suggestive of sub-clinical pulmonary vasculopathy in patients 
carrying ACA. 
 
The major limitation of this study is our inability to report PFT associations 
with a more robust assessment of dyspnoea and exercise tolerance. 
Nonetheless, we carefully excluded all patients with established pulmonary 
disease and those in which pulmonary complications had been suspected. 
Furthermore, the case notes of all patients with an FVC:TLCO ratio >2.0 were 
scrutinised to ensure that there were no additional grounds for further 
investigation of this finding. It could be argued that our findings include a 
number of patients carrying ACA who will subsequently develop established 
PAH. Whilst this is possible, previous studies have shown that the frequency 
of PAH is similar in ACA-positive and ACA-negative patients with SSc (6). 
Furthermore, the ACA-negative group comprised a large number of patients 
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with anti-nucleolar auto-antibodies (17.2%) who have a comparable, if not 
greater, risk of future pulmonary vascular complications (2). The TTE data did 
not suggest the ACA-positive group were more likely to develop PAH than the 
ACA-negative group, although estimated RSVP values were only available in 
37% of assessments, highlighting an important limitation of TTE screening for 
PAH in SSc.  
 
Our findings suggest patients with ACA, without pulmonary complications, 
have PFT abnormalities consistent with indolent increased pulmonary 
vascular resistance, despite the majority of these patients not going on to 
develop PAH. The long-term sequalae of PFT abnormalities in patients with 
ACA who do not subsequently develop PAH, is unknown. 
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Figure 1. Differences in the FVC:TLco ratio in patients who are ACA 
positive and ACA negative. The median, interquartile range and range are 
represented by the horizontal bar, box plots and whiskers respectively. FVC, 
forced vital capacity; TLco, gas transfer factor; ACA, anticentromere 
antibodies.  
 
 
 
